Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Adcom 2-9 Against Label Expansion

|Includes: Amarin Corporation PLC (AMRN)

The panel vote seemed like a shock to everyone, although AF had the right and best read on how FDA would treat the situation. I stuck by my thesis, FDA panel did not pan out.

I believe company needs to step back, partner Marine and drive to successful R-It results - in the absence of another complete shock on Dec. 20th (meaning in the unlikely event FDA ignored the panel as they ignored the SPA, and get approval)

Sentiment is hold, with trading range-bound until further news develops around forward strategy on both Marine and Anchor, $4-7.